Thermo Fisher Scientific Inc.’s Stock Price Drops to $406.05, Experiencing a 5.34% Decline

Thermo Fisher Scientific Inc. (TMO)

406.05 USD -22.90 (-5.34%) Volume: 3.2M

Thermo Fisher Scientific Inc.’s stock price stands at 406.05 USD, experiencing a significant trading session drop of 5.34%, with a trading volume of 3.2M. Facing a notable YTD decline of 21.95%, TMO’s stock performance indicates a challenging market scenario.

Latest developments on Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. stock experienced a decline on Wednesday, underperforming the overall market. This drop comes amidst significant company news, including the introduction of an Automated Plasmid DNA Purification Kit and a partnership with RoosterBio on Cell Therapies. Additionally, Thermo Fisher recently presented at the BofA Securities 2025 Healthcare Conference, discussing their future plans. The stock price movement may also be influenced by external factors such as tariffs impacting the company, although the valuation is expected to compensate over time. Looking ahead, the company remains a key player in the Digital PCR Market, with projections showing growth and potential for the future.

Thermo Fisher Scientific Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma are bullish on Thermo Fisher Scientific Inc, citing the company’s latest expansion in pharmaceutical services as a driving force behind their optimism. In their research report, they highlight the company’s Q1 2025 earnings report, which showed a solid revenue of $10.36 billion and an adjusted operating income of $2.27 billion. Despite facing challenges in the macroeconomic landscape, Thermo Fisher Scientific’s adjusted operating margin stood at 21.9%, with an adjusted EPS of $5.15, reflecting a 1% year-over-year growth.

Furthermore, Baptista Research‘s analysis on Thermo Fisher Scientific’s shift toward contract research and manufacturing is positive, with a focus on major drivers for growth. In their report on the company’s performance in the fourth quarter of 2024, analysts noted a 5% year-over-year growth in revenue, reaching $11.4 billion, and a 7% increase in adjusted operating income, totaling $2.72 billion. The adjusted operating margin expanded by 50 basis points to 23.9%, while adjusted earnings per share (EPS) grew by 8% to $6.10, showcasing the company’s potential for future success.

A look at Thermo Fisher Scientific Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Thermo Fisher Scientific Inc, a company that manufactures scientific instruments and chemicals, has a mixed outlook according to Smartkarma Smart Scores. While the company scores well in terms of momentum, indicating strong market performance, it falls short in areas such as dividend and value. With an overall score of 3 out of 5 for growth and resilience, Thermo Fisher Scientific Inc shows potential for future expansion and stability in the market.

Despite facing challenges in certain areas, Thermo Fisher Scientific Inc remains a key player in the scientific instruments industry. The company’s strong momentum score suggests a positive market sentiment and potential for growth. While the scores for value and dividend are not as high, the company’s resilience score indicates a level of stability. Overall, Thermo Fisher Scientific Inc‘s Smartkarma Smart Scores paint a picture of a company with room for growth and a solid foundation in the market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma